PH Could be Next Vaccine Manufacturing Site

The Philippines is expected to be a coronavirus disease 2019 (COVID-19) vaccine manufacturing site in the future as Filipino pharmaceutical firm Glovax Biotech teams up with Korean vaccine manufacturers.

The partnership was made to produce the COVID-19 vaccine EuCorVac-19 on Filipino soil.

Glovax is currently negotiating with the Department of Trade and Industry (DTI) for future investments on the said next gen vaccine manufacturing site.

Around 40 million doses of EuCorVac-19 are expected to be purchased by the government. Moreover, the company will invest P7 billion for technology and manufacturing.

According to Glovax, the local vaccine plant is capable of producing 100 million doses of vaccine every year.

“Glovax and Eubiologics are in the process of applying for the Emergency Use Authorization (EUA),” Glovax said in a statement.

Since 2003, Glovax has sold more than 5 million doses of different vaccines against measels, tuberculosis, polio and rabies. (MLC)